INS and type 2 diabetes mellitus: In this study, although plasma glucose levels remained unchanged during the experiments, short-term treatment of telmisartan (2 weeks) decreased plasma insulin, TG, and NEFA levels in KK-Ay mice, an obese type 2 diabetic animal model.